Bone is a privileged site of metastases for large primary tumors. After the lung and the liver, the skeleton is the most common site where cancer cells metastases are diagnosed and about 70% of patients with an advanced prostate or breast cancer present bone metastases.

In fact, in two-third of patients, the presence of bone metastases is associated with a decrease in the quality of life as a result of severe pain, fractures and other skeletal events. So an adequate management of pain is essential to propose an optimal treatment and to take into account the impact of pain in daily activities and psychological state in patients with metastatic bone disease.

Animal models are indispensable to investigate the pathogenesis of bone metastases in vivo and to conduct preclinical pharmacological trials. Most of animal models of mammary and prostate carcinoma in animals do not easily metastasize to bone that is why most preclinical studies used local administration like inoculation of cancer cells directly into the tibia or femur.